Key Takeaways
- • Advent International proposes take-private transaction at $1.02 per share, seeking to acquire all outstanding shares of Definitive Healthcare while already holding a 58.5% controlling stake as of September 2, 2026.
- • Jason Krantz, Definitive Healthcare founder and Executive Chairman, holds 17.6% stake and signals potential rollover support, filing a Schedule 13D on September 2 that converts his prior Schedule 13G status—indicating willingness to roll equity into the surviving post-deal company rather than cash out.
- • Deal structure contingent on founder equity rollover, with Advent's offer premised on Krantz converting his Class A common stock and LLC Units into equity of the surviving entity, though no binding obligation currently exists.
- • Krantz reserves full termination optionality, explicitly stating he may modify or withdraw consideration at any time and retains the right to pursue alternative paths including third-party proposals, additional share purchases, or sales if the deal does not materialize.
- • Significant insider alignment on transaction, with combined Advent (58.5%) and Krantz (17.6%) positions representing 76.1% of Class A common stock, substantially reducing minority shareholder risk and signaling high likelihood of deal completion pending special committee and regulatory approval.
Summary
Advent International, the multinational private equity firm, formally proposed a take-private transaction for healthcare data analytics company Definitive Healthcare Corp. on September 1, 2026, with an offer price of $1.02 per share for all shares the firm does not currently own. Advent's controlling stake in the company stands at 58.54% of Class A common stock, positioning the PE firm to drive the transaction forward. The proposal was disclosed through SEC filings on September 2, 2026.
Jason Ronald Krantz, Definitive Healthcare's founder and Executive Chairman, holds a 17.6% beneficial ownership stake in Class A common stock and disclosed his position through a Schedule 13D filing on the same date, converting from a prior Schedule 13G status. This filing conversion signals a material change in Krantz's disclosure obligations and—critically for deal success—indicates his potential willingness to support the transaction through an equity rollover structure rather than demanding immediate cash consideration. According to Krantz's disclosure, Advent's proposal is explicitly "premised on the Reporting Person rolling over all his Class A Common Stock and LLC Units into equity of the surviving company."
Krantz stated he will engage in discussions with Advent International and the company's special committee regarding the transaction terms. However, he emphasized that "no binding obligation" currently constrains his decision and that he "reserves the right to modify or withdraw at any time" his consideration of the deal. This language preserves optionality for the founder, who noted that absent a transaction, he may evaluate alternative pathways including third-party acquisition proposals, incremental share purchases, or equity sales. His position as Executive Chairman provides him material influence over the company's strategic direction and board deliberations.
The combined positions of Advent (58.5%) and Krantz (17.6%) represent 76.1% of outstanding Class A common stock, substantially reducing minority shareholder liquidity risk and substantially de-risking deal completion from a shareholder vote perspective. The structure appears designed to provide Krantz with continued equity upside participation in a private company context while allowing Advent to fully consolidate ownership. The special committee, comprised of independent directors, will likely manage the fairness opinion process and negotiate final terms on behalf of minority shareholders, though the insider stake concentrations suggest a relatively streamlined approval pathway.
Jason Ronald Krantz, Definitive Healthcare's founder and Executive Chairman, holds a 17.6% beneficial ownership stake in Class A common stock and disclosed his position through a Schedule 13D filing on the same date, converting from a prior Schedule 13G status. This filing conversion signals a material change in Krantz's disclosure obligations and—critically for deal success—indicates his potential willingness to support the transaction through an equity rollover structure rather than demanding immediate cash consideration. According to Krantz's disclosure, Advent's proposal is explicitly "premised on the Reporting Person rolling over all his Class A Common Stock and LLC Units into equity of the surviving company."
Krantz stated he will engage in discussions with Advent International and the company's special committee regarding the transaction terms. However, he emphasized that "no binding obligation" currently constrains his decision and that he "reserves the right to modify or withdraw at any time" his consideration of the deal. This language preserves optionality for the founder, who noted that absent a transaction, he may evaluate alternative pathways including third-party acquisition proposals, incremental share purchases, or equity sales. His position as Executive Chairman provides him material influence over the company's strategic direction and board deliberations.
The combined positions of Advent (58.5%) and Krantz (17.6%) represent 76.1% of outstanding Class A common stock, substantially reducing minority shareholder liquidity risk and substantially de-risking deal completion from a shareholder vote perspective. The structure appears designed to provide Krantz with continued equity upside participation in a private company context while allowing Advent to fully consolidate ownership. The special committee, comprised of independent directors, will likely manage the fairness opinion process and negotiate final terms on behalf of minority shareholders, though the insider stake concentrations suggest a relatively streamlined approval pathway.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.